Biotechnology company Syros Pharmaceuticals has raised $53m in a series B round that included Wuxi PharmaTech to develop its gene-control cancer treatment.
Syros Pharmaceuticals, a US-based developer of control therapies to treat cancer, has raised $53m in a series B round featuring biopharmaceutical company Wuxi PharmaTech.
Venture capital firms Polaris Partners, Flagship Ventures, Alexandria Venture Investments and Arch Venture Partners, investment firm Aisling Capital and hedge fund Redmile Group joined Wuxi PharmaTech, which invested through its Wuxi Pharmatech Corporate Venture Fund, in the round.
Syros Pharmaceuticals is focused on discovering and developing novel gene control therapies. The funds will be invested in…
